Stanley Jordan

Director, Division of Nephrology · Cedars-Sinai Medical Center

Credentials: · · · · ·

History

Rituximab and intravenous immune globulin for desensitization during renal transplantation
New England Journal of Medicine · 2008 · Last of 9 authors · 545 citations
Cell-Free DNA and Active Rejection in Kidney Allografts
Journal of the American Society of Nephrology · 2017 · 478 citations
Update on the use of immunoglobulin in human disease: A review of evidence
Review · Journal of Allergy and Clinical Immunology · 2017 · 472 citations

Intra-Graft C1 Esterase Inhibitor Therapy for Deceased Kidney Transplantation
National Institute of Allergy and Infectious Diseases · U01
PI · $4.4M · Cedars-Sinai Medical Center
2024–2031
Intra-Graft C1 Esterase Inhibitor Therapy for Deceased Kidney Transplantation
National Institute of Allergy and Infectious Diseases · R01
PI · $2.2M · Cedars-Sinai Medical Center
2024–2031
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $20.4K · Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center
2003–2005
Iv Ig Modulation of Alloimmune Responses in vivo
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $1.6M · Cedars-Sinai Medical Center
1994–2002

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Principal investigator · Active not recruiting · Phase 1, Phase 2
Stanley Jordan, MD
2018–2025
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
Principal investigator · Completed · Phase 1, Phase 2
Stanley Jordan, MD
2018–2024
Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation
Principal investigator · Completed · Phase 1, Phase 2
Cedars-Sinai Medical Center
2015–2017
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
Principal investigator · Completed · Phase 1, Phase 2
Cedars-Sinai Medical Center
2014–2017